Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin.

Abstract

INTRODUCTION:

Hepatitis E virus (HEV) is an emerging cause of autochthonous-acute-hepatitis and acute-on-chronic-liver-failure in western countries. Treatment is not routinely used, despite ribavirin has a good antiviral effect. In vitro sofosbuvir inhibits HEV replication, but clinical data are lacking.

CASE REPORT:

We report a case of acute-on-chronic-liver-failure due to HEV treated with sofosbuvir and ribavirin. The treatment was capable of rapidly inducing both HCV and HEV viral suppression.

CONCLUSION:

In conclusion, although more data are required before firm conclusions could be drawn, the combination of sofosbuvir and ribavirin in not immunosuppressed patients with acute hepatitis E may be able to clear HEV infection.

• Authors: Elisa Biliotti, Cristiana Franchi, Martina Spaziante, Anna Rosa Garbuglia, Lorenzo Volpicelli, Donatella Palazzo, Maurizio De Angelis, Rozenn Esvan, Gloria Taliani
• Journal: Infection (Infection) Vol. 46 Issue 5 Pg. 725-727 (Oct 2018) ISSN: 1439-0973 [Electronic] Germany
• PMID: 29946850 (Publication Type: Case Reports, Journal Article)

Chemical References

• Biomarkers
• Ribavirin
• Sofosbuvir

Topics

• Acute-On-Chronic Liver Failure (diagnosis, drug therapy, virology)
• Biomarkers
• Coinfection
• Drug Therapy, Combination
• Fatal Outcome
• Hepatitis E (diagnosis, drug therapy, transmission, virology)
• Humans
• Liver Function Tests
• Male
• Middle Aged
• Ribavirin (administration & dosage, therapeutic use)
• Shock, Septic
• Sofosbuvir (administration & dosage, therapeutic use)
• Treatment Outcome
• Viral Load